Company intelligence / Profile preview

BioActor

Maastricht, Limburg, Netherlandssolabianutrition.com ↗

Ownership: Private
Employees: ~24
Development stage: Other

Overview

BioActor develops clinically evaluated bioactive ingredients—primarily polyphenols—for use in dietary supplements and functional foods. Their products address chronic health concerns such as diabetes, osteoporosis, cardiovascular disease, metabolic syndromes, healthy aging, and active living. The company has demonstrated clinical efficacy for its patented substances but does not develop pharmaceuticals per se. In January 2023 BioActor was acquired by Solabia but continues to operate as an innovation center within Solabia’s nutrition division.

Therapeutic areas: OtherMetabolic DisordersCardiovascularEndocrinology
Modalities: Small moleculeProteinPeptides
Industry: Food & Nutrition

Partnerships

Works with leading marketers of dietary supplements and functional foods at the B2B level.

Beyond the preview

Go deeper on BioActor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioActor.

Explore the full profile